GordonMD Global Investments reports $16 million Pyxis Oncology common share purchase

• GordonMD Global Investments, a 10% owner of Pyxis Oncology, disclosed a purchase of 5,517,000 common shares.
• Beneficial ownership rose to 15,541,909 shares, held indirectly through GordonMD Long Biased Master Fund.
• The filing also reports the purchase of 7,546,766 common stock purchase warrants with a $3.50 exercise price.
• Warrants are not exercisable until stockholder approval increases authorized common shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000919574-26-006609), on October 02, 2026, and is solely responsible for the information contained therein.